Katanov Christina, Lerrer Shalom, Liubomirski Yulia, Leider-Trejo Leonor, Meshel Tsipi, Bar Jair, Feniger-Barish Rotem, Kamer Iris, Soria-Artzi Gali, Kahani Hadar, Banerjee Debabrata, Ben-Baruch Adit
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv, 6997801, Israel.
Department of Pathology, Tel Aviv Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv, 64239, Israel.
Stem Cell Res Ther. 2015 May 1;6(1):87. doi: 10.1186/s13287-015-0080-7.
Breast cancer progression is promoted by stromal cells that populate the tumors, including cancer-associated fibroblasts (CAFs) and mesenchymal stem/stromal cells (MSCs). The activities of CAFs and MSCs in breast cancer are integrated within an intimate inflammatory tumor microenvironment (TME) that includes high levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β). Here, we identified the impact of TNF-α and IL-1β on the inflammatory phenotype of CAFs and MSCs by determining the expression of inflammatory chemokines that are well-characterized as pro-tumorigenic in breast cancer: CCL2 (MCP-1), CXCL8 (IL-8) and CCL5 (RANTES).
Chemokine expression was determined in breast cancer patient-derived CAFs by ELISA and in patient biopsies by immunohistochemistry. Chemokine levels were determined by ELISA in (1) human bone marrow-derived MSCs stimulated by tumor conditioned media (Tumor CM) of breast tumor cells (MDA-MB-231 and MCF-7) at the end of MSC-to-CAF-conversion process; (2) Tumor CM-derived CAFs, patient CAFs and MSCs stimulated by TNF-α (and IL-1β). The roles of AP-1 and NF-κB in chemokine secretion were analyzed by Western blotting and by siRNAs to c-Jun and p65, respectively. Migration of monocytic cells was determined in modified Boyden chambers.
TNF-α (and IL-1β) induced the release of CCL2, CXCL8 and CCL5 by MSCs and CAFs generated by prolonged stimulation of MSCs with Tumor CM of MDA-MB-231 and MCF-7 cells. Patient-derived CAFs expressed CCL2 and CXCL8, and secreted CCL5 following TNF-α (and IL-1β) stimulation. CCL2 was expressed in CAFs residing in proximity to breast tumor cells in biopsies of patients diagnosed with invasive ductal carcinoma. CCL2 release by TNF-α-stimulated MSCs was mediated by TNF-RI and TNF-RII, through the NF-κB but not via the AP-1 pathway. Exposure of MSCs to TNF-α led to potent CCL2-induced migration of monocytic cells, a process that may yield pro-cancerous myeloid infiltrates in breast tumors.
Our novel results emphasize the important roles of inflammation-stroma interactions in breast cancer, and suggest that NF-κB may be a potential target for inhibition in tumor-adjacent stromal cells, enabling improved tumor control in inflammation-driven malignancies.
肿瘤中的基质细胞,包括癌症相关成纤维细胞(CAFs)和间充质干/基质细胞(MSCs),会促进乳腺癌的进展。CAFs和MSCs在乳腺癌中的活性在一个紧密的炎性肿瘤微环境(TME)中整合在一起,该微环境包括高水平的肿瘤坏死因子α(TNF-α)和白细胞介素1β(IL-1β)。在此,我们通过确定在乳腺癌中具有明确促肿瘤作用的炎性趋化因子的表达,来确定TNF-α和IL-1β对CAFs和MSCs炎性表型的影响:CCL2(单核细胞趋化蛋白-1,MCP-1)、CXCL8(白细胞介素-8,IL-8)和CCL5(调节激活正常T细胞表达和分泌因子,RANTES)。
通过酶联免疫吸附测定法(ELISA)在源自乳腺癌患者的CAFs中测定趋化因子表达,并通过免疫组织化学在患者活检组织中进行测定。通过ELISA在以下情况中测定趋化因子水平:(1)在MSC向CAF转化过程结束时,由乳腺肿瘤细胞(MDA-MB-231和MCF-7)的肿瘤条件培养基(肿瘤CM)刺激的人骨髓来源的MSCs;(2)肿瘤CM来源的CAFs、患者来源的CAFs以及由TNF-α(和IL-1β)刺激的MSCs。分别通过蛋白质免疫印迹法以及针对c-Jun和p65的小干扰RNA(siRNAs)分析AP-1和核因子κB(NF-κB)在趋化因子分泌中的作用。在改良的博伊登小室中测定单核细胞的迁移。
TNF-α(和IL-1β)诱导了由MDA-MB-231和MCF-7细胞的肿瘤CM长期刺激产生的MSCs和CAFs释放CCL2、CXCL8和CCL5。源自患者的CAFs表达CCL2和CXCL8,并在TNF-α(和IL-1β)刺激后分泌CCL5。在浸润性导管癌患者的活检组织中,CCL2在紧邻乳腺肿瘤细胞的CAFs中表达。TNF-α刺激的MSCs释放CCL2是由TNF受体I型(TNF-RI)和TNF受体II型(TNF-RII)介导的,通过NF-κB途径而非AP-1途径。MSCs暴露于TNF-α导致CCL2强力诱导单核细胞迁移,这一过程可能在乳腺肿瘤中产生促癌性髓系浸润。
我们的新结果强调了炎症与基质相互作用在乳腺癌中的重要作用,并表明NF-κB可能是肿瘤邻近基质细胞中抑制作用的潜在靶点,从而在炎症驱动的恶性肿瘤中实现更好的肿瘤控制。